Skip to content
Hair Pipeline
← Back to the pipeline

TDM-105795

A topical thyroid hormone receptor agonist — an unusual and largely untried lever.

Phase 2TopicalThyroid hormone receptor
Developed by
TechnoDerma Medicines
Current phase
Phase 2

Tests whether it works, at what dose, in a few hundred people.

Partners
Cutia Therapeutics
Indications
Androgenetic alopecia
Also known as
TDM105795, CU-40101
Last public activity
November 2025
Record confidence
Medium

Development history

  1. Phase 1Phase 2

    First Phase 2 trial on record: NCT05802173 — Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

    ClinicalTrials.gov ↗
  2. Phase 1

    First Phase 1 trial on record: NCT04913519 — A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT05802173Phase 2COMPLETED

    Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

    Technoderma Medicines Inc. · n=71 · March 2023

  • NCT05380427Phase 1COMPLETED

    A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects

    Cutia Therapeutics（Wuxi）Co.,Ltd · n=80 · August 2022

  • NCT05244980Phase 1COMPLETED

    A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

    Technoderma Medicines Inc. · n=32 · February 2022

  • NCT04913519Phase 1COMPLETED

    A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)

    Technoderma Medicines Inc. · n=30 · April 2021

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources